eletriptan (Rx)

Brand and Other Names:Relpax
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 20mg
  • 40mg
more...

Migraine Headache

20-40 mg PO at onset of symptoms; repeat dose after 2 hr if necessary

Not to exceed 80 mg/day

Renal Impairment

Monitor for increase in blood pressure; dose adjustment not necessary

Hepatic Impairment

Mild to moderate impairment: Dose adjustment not necessary

Severe impairment: Do not administer

<18 years old: Not recommended

Migraine headache: See adult dosing

Next:

Interactions

Interaction Checker

and eletriptan

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Asthenia (5-10%)

            Dizziness (5-10%)

            Headache (5-10%)

            Somnolence (5-10%)

            Nausea (5-10%)

            Chest pain/tightness (1-4%)

            Palpitation (>1%)

            Flushing (>1%)

            Chills (>1%)

            Hypertonia (>1%)

            Hypoesthesia (>1%)

            Pain (>1%)

            Paresthesia (>1%)

            Vertigo (>1%)

            Weakness (>1%)

            Abdominal pain/discomfort (>1%)

            Dysphagia (>1%)

            Dyspepsia (>1%)

            Xerostomia (>1%)

            Back pain (>1%)

            Pharyngitis (>1%)

            Diaphoresis (>1%)

            Postmarking Reports

            Cardiac ischemia

            Seizures

            Vomiting

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity, including angioedema and anaphylaxis

            History of CAD or coronary artery vasospasm

            Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders

            History of stroke or TIA, or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke

            Peripheral vascular disease

            Ischemic bowel disease

            Uncontrolled hypertension

            Severe hepatic impairment

            Do not use within 24 hr of another 5-HT1 agonist or ergot derivative

            Within at least 72 hr of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir

            Cautions

            Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache)

            Myocardial ischemia/infarction or Prinzmetal’s angina reported (see Contraindications)

            Life-threatening cardiac rhythm disturbances including VT and VFIB leading to reported within a few hr following the administration of 5-HT1 agonists

            Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities

            Sensations of tightness, pain, and pressure in the chest, throat, neck, and jaw commonly occur after treatment and are usually non-cardiac in origin; however, perform a cardiac evaluation in patients at high cardiac risk

            Significant increase in blood pressure including hypertensive crisis with acute impairment of organ systems reported

            Anaphylaxis/anaphylactoid and hypersensitivity reactions, including angioedema reported (see Contraindications)

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Enters breast milk; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective 5-HT1 receptor agonist in cranial arteries. Causes vasoconstriction and reduces inflammation associated with antidronic neuronal transmission associated with relief of migraine

            Pharmacokinetics

            Half-Life elimination: 4 hr

            Peak Plasma Time: 1.5-2 hr

            Bioavailability: 50%

            Protein bound: 85%

            Vd: 138 L

            Metabolism: hepatic CYP3A4

            Metabolites: N-demethylated eletriptan (10-20%)

            Renal Clearance: 3.9 L/hr

            Excretion: 90% Non-renal

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.